Literature DB >> 16152758

The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.

Hagen Bode1, Luzie Lenzner, Oliver Holger Kraemer, Anton Josef Kroesen, Kerstin Bendfeldt, Jörg Dieter Schulzke, Michael Fromm, Gisela Stoltenburg-Didinger, Martin Zeitz, Reiner Ullrich.   

Abstract

BACKGROUND AND AIMS: Diarrhoea is a frequent adverse effect of HIV protease inhibitors (PIs) which may be due to intestinal barrier disruption. We investigated whether tight junction dysregulation, apoptosis or necrosis are responsible for this epithelial damage.
METHODS: Saquinavir, nelfinavir, and ritonavir were added to the mucosal or serosal side of HT-29/B6 colon cell monolayers. Transepithelial resistance was monitored for 72 h to assess epithelial barrier function. Apoptosis and necrosis were investigated by light and electron microscopy and quantified by nucleosome ELISA and LDH measurement, respectively. Tight junction components were analysed by Western blots of occludin and zonula occludens. Apoptosis induction in normal human intestinal epithelium was examined by measurement of poly(ADP-ribose) polymerase (PARP) cleavage in Western blots of mucosal tissue explants cultured with PIs for 24 h.
RESULTS: HIV PIs decreased transepithelial resistance by more than 44% in HT-29/B6 monolayers. Histology revealed massive apoptotic body formation but no evidence for necrosis after PI treatment. Correspondingly, LDH release was lower than 0.2%/h of total LDH, independent of PI treatment, and nucleosomes were increased up to 22-fold after drug treatment versus control. Occludin and zonula occludens-1 expression in the membrane were not diminished. PARP cleavage increased in normal human intestinal tissue treated with PIs.
CONCLUSIONS: PI-induced barrier disruption in intestinal epithelial cells is not due to necrosis or tight junction alterations, but to induction of massive apoptosis which may lead to leak-flux diarrhoea in vivo. Our findings suggest that induction of apoptosis by PIs could have potential for antitumour therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16152758

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  14 in total

1.  HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Authors:  Scott R Richmond; Michael J Carper; Xiaoyong Lei; Sheng Zhang; Kevin E Yarasheski; Sasanka Ramanadham
Journal:  Biochim Biophys Acta       Date:  2010-02-01

2.  Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.

Authors:  Bokai Lei; Weibin Zha; Yun Wang; Cong Wen; Elaine J Studer; Xuan Wang; Fang Jin; Guangji Wang; Luyong Zhang; Huiping Zhou
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

3.  Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors:  Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

4.  Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy.

Authors:  Hubert Schulbin; Hagen Bode; Hartmut Stocker; Wolfgang Schmidt; Thomas Zippel; Christoph Loddenkemper; Elisabeth Engelmann; Hans-Jörg Epple; Keikawus Arastéh; Martin Zeitz; Reiner Ullrich
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

5.  Protective effects of alanyl-glutamine supplementation against nelfinavir-induced epithelial impairment in IEC-6 cells and in mouse intestinal mucosa.

Authors:  Manuel B Braga-Neto; Bruna M C Oliveira; Raphael S Rodrigues; Francisco J Noronha; Renata F Leitao; Gerly A C Brito; Aldo A Lima; Richard L Guerrant; Cirle A Warren
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

6.  HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

Authors:  Xudong Wu; Lixin Sun; Weibin Zha; Elaine Studer; Emily Gurley; Li Chen; Xuan Wang; Phillip B Hylemon; William M Pandak; Arun J Sanyal; Luyong Zhang; Guangji Wang; Jie Chen; Jian-Ying Wang; Huiping Zhou
Journal:  Gastroenterology       Date:  2009-09-02       Impact factor: 22.682

Review 7.  HIV protease inhibitors in gut barrier dysfunction and liver injury.

Authors:  Xudong Wu; Yunzhou Li; Kesong Peng; Huiping Zhou
Journal:  Curr Opin Pharmacol       Date:  2014-08-06       Impact factor: 5.547

8.  Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

Authors:  Manuel B Braga Neto; Carolina V Aguiar; Jamilly G Maciel; Bruna M C Oliveira; Jesus E Sevilleja; Reinaldo B Oriá; Gerly A C Brito; Cirle A Warren; Richard L Guerrant; Aldo A M Lima
Journal:  BMC Gastroenterol       Date:  2010-08-11       Impact factor: 3.067

9.  The influence of hospitalization and HIV severity on gastrointestinal PCR panel evaluation of HIV-related acute diarrhea in New York City: a retrospective, cross-sectional study.

Authors:  Abhishek Verma; Ashley M Hine; Andrew Joelson; Rena Mei; Robert A Pitts; Benjamin Lebwohl; Jordan E Axelrad
Journal:  Therap Adv Gastroenterol       Date:  2022-04-28       Impact factor: 4.802

10.  Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.

Authors:  Joseph Gathe; Jose R Arribas; Jan Van Lunzen; Will Garner; Rebecca M Speck; Randall Bender; Sanatan Shreay; Thai Nguyen
Journal:  Patient       Date:  2015-10       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.